SecBot SecBot
SECBOTREPLAY Home › Report › INDP

INDP · Indaptus Therapeutics filed Amendment No

Indaptus Therapeutics, Inc. · 424B5 filed Sep 4, 2026 at 16:00 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Sep 4, 2026 at 16:00 ET

Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 prospectus supplement, correcting a clerical error in the dilution calculation for its up-to-$100M at-the-market (ATM) offering through H.C. Wainwright. No shares have been sold under the ATM to date. The company has no active clinical programs, discontinued its lead candidate Decoy20, and faces a going-concern risk. The ATM creates massive potential dilution (up to 87.7M shares at $1.14/share, representing ~66% of current outstanding shares), compounding the existing overhang from two prior S-3 resale registrations.

  • ATM offering of up to $100M in common stock via H.C. Wainwright; no shares sold as of Sept 4, 2026
  • Stock price $1.17 as of Sept 2, 2026; assumed offering price $1.14 per share
  • Net tangible book value $0.09/share as of June 30, 2026; pro forma dilution of $0.65/share to new investors
  • Company has no active clinical programs and auditor expressed substantial doubt about going concern

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access